Hansa Biopharma AB (publ) (OM: HNSA)
Health Care · Biotechnology · SE
Skr36.12
+0.44% today · -6.8% 1Y
Hansa Biopharma AB (publ) (OM: HNSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $365.97M and employs 131 people.
Over the last twelve months the share price has lost 6.8%, trading between 23.52 and 48.22.
Tweenvest scores Hansa Biopharma AB (publ) across four factors: quality 24/100, value 69/100, growth 100/100. Its strongest factor is growth.
HNSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $365.97M
- Revenue (TTM)
- $19.55M
- P/E
- —
- EPS
- -7.74
- Dividend yield
- —
- Beta (5Y)
- 1.66
- 52-week high
- Skr48.22
- 52-week low
- Skr23.52
- Avg volume (3M)
- —
- Shares outstanding
- 101.76M
- Employees
- 131
- Next earnings
- —
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
- ISIN
- SE0002148817
- Founded
- 2007
- Listed since
- Oct 17, 2007
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beijing Luzhu Biotechnology Co., Ltd.SEHK: 2480 | $380.46M | HK$15.01 | +12.01% |
| AbClon Inc.KOSDAQ: A174900 | $379.19M | ₩25,550.00 | -8.42% |
| C4 Therapeutics, Inc.NasdaqGS: CCCC | $376.46M | $3.06 | -3.16% |
| Fennec Pharmaceuticals Inc.NasdaqCM: FENC | $375.57M | $10.72 | +0.09% |
| ProKidney Corp.NasdaqCM: PROK | $363.53M | $1.67 | -4.02% |
| PureTech Health plcLSE: PRTC | $360.13M | £1.13 | +1.44% |
| Inhibikase Therapeutics, Inc.NasdaqCM: IKT | $358.69M | $1.85 | -6.35% |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | $358.24M | $12.30 | -1.60% |
Figures last refreshed Oct 11, 2026.